Gene Therapy Market Size, Share & Trends Analysis Report By Indication (Cancer, Genetic Disorders, Infectious Diseases, CVD, Neuro Disorders), By Vector Type (Viral, Non-Viral), By Region, and Segment Forecasts, 2018 - 2026

  • ID: 4582031
  • Report
  • 120 pages
  • Grand View Research
1 of 4

FEATURED COMPANIES

  • Benitec BioPharma
  • Calimmune Inc.
  • Chiesi Farmaceutici S.p.A
  • Juno Therapeutics, Inc.
  • Sangamo Biosciences Inc.,
  • Sibiono GeneTech Co. Ltd
  • MORE
The global gene therapy market size is expected to reach USD 39.54 million by 2026. Rising competition among manufacturers and high number of molecules in pipeline are supporting the growth of the market.

Gene therapy development is aimed to cure rare diseases and even some hereditary diseases, which are caused by a mutated or faulty gene. Moreover, ever-increasing need for new cures for orphan diseases and rising incidence of cancer caused due to mutations in genes are likely to stir up the demand for gene therapy.

As of early 2016, there were more than 1000 molecules in the pipeline in various clinical phases. However, around 76.0% of the molecules are in the developmental or preclinical stages and expected to hit the market in late 2020’s.

A great number of large pharma/biotech players are estimated to acquire small firms as many have been trying to develop in-house expertise and build their own pipelines. This trend is anticipated to help the market gain tremendous traction over the coming years. Combination of gene therapy with small molecules or protein therapy is said to have lesser side effects and better efficacy as compared to gene therapy alone.

Cancer held the dominant share in the market in 2017 owing to relatively high adoption of gene therapies for cancer treatment. Continual rise in new cancer cases and related mortality per year triggers the need for development of robust treatment options. Ongoing developments in cancer gene studies have provided significant information about cancer-related molecular signatures, which in turn, is projected to support ongoing clinical trials for cancer therapeutics

Further Key Findings from the Study Suggest:
  • More than 60.0% of the market is occupied by cancer research owing to a large pipeline.
  • Adenoviral vectors are the most used in pipeline development, closely followed by retroviral vectors.
  • Europe and the U.S. are poised to occupy the largest cumulative share in the market throughout the forecast period.
  • Asia Pacific is set to post noteworthy CAGR during the forecast period, owing to growing pipeline molecules and a large number of companies competing in the market.
  • Some of the key players in this market are UniQure N.V, Spark Therapeutics LLC, Bluebird Bio, Juno Therapeutics, GlaxoSmithKline, Celgene Corporation, Shire Plc, Sangamo Biosciences, Dimension Therapeutics, Voyager Therapeutics, Human Stem Cell Institute, Bristol Myer’s Squibb, and Chiesi Farmaceutici S.p.A.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Benitec BioPharma
  • Calimmune Inc.
  • Chiesi Farmaceutici S.p.A
  • Juno Therapeutics, Inc.
  • Sangamo Biosciences Inc.,
  • Sibiono GeneTech Co. Ltd
  • MORE

Chapter 1 Executive Summary

Chapter 2 Market Snapshot

Chapter 3 Market Variables, Trends & Scope
3.1 Market segmentation & scope
3.1.1 Market Driver Analysis
3.1.1.1 Robust pipeline in development
3.1.1.2 Introduction of technological advancements
3.1.1.3 Increasing investment from the companies and partnerships
3.1.1.4 Growing prevalence of target diseases and increased demand for innovative medicine
3.1.2 Market Restrain Analysis
3.1.2.1 Presence of ambiguous regulatory framework
3.1.2.2 High prices of gene therapy medicines
3.2 Penetration & growth prospect mapping
3.3 Gene Therapy - SWOT Analysis, By Factor (political & legal, economic and technological)
3.4 Industry Analysis - Porter’s

Chapter 4 Gene Therapy Market: Indication Type Estimates & Trend Analysis
4.1 Gene Therapy market: Indication Type movement analysis
4.2 Cancer
4.2.1 Cancer market, 2014 - 2026 (USD Million)
4.3 Cardiovascular Indication
4.3.1 Cardiovascular Indication market, 2014 - 2026 (USD Million)
4.4 Infectious diseases indication
4.4.1 Infectious diseases indication, 2014 - 2026 (USD Million)
4.5 Genetic diseases indication
4.5.1 Genetic diseases indication, 2014 - 2026 (USD Million)
4.6 Neurological diseases indication
4.6.1 Neurological diseases indication, 2014 - 2026 (USD Million)
4.7 Other indications
4.7.1 Other indications, 2014 - 2026 (USD Million)

Chapter 5 Gene Therapy Market: Vector type Estimates & Trend Analysis
5.1 Gene Therapy market: Vector type movement analysis
5.2 Viral Vectors
5.2.1 Viral Vector market, 2014 - 2026 (USD Million)
5.2.2 Retrovirus market, 2014 - 2026 (USD Million)
5.2.3 Adenovirus market, 2014 - 2026 (USD Million)
5.2.4 Adeno-associated virus market, 2014 - 2026 (USD Million)
5.2.5 Vaccinia virus market, 2014 - 2026 (USD Million)
5.2.6 Herpes simplex virus market, 2014 - 2026 (USD Million)
5.2.7 Other viral vectors market, 2014 - 2026 (USD Million)
5.3 Non-viral vectors
5.3.1 Non-viral vectors market, 2014 - 2026 (USD Million)
5.3.2 Injection of naked DNA market, 2014 - 2026 (USD Million)
5.3.3 Lipofection market, 2014 - 2026 (USD Million)
5.3.4 Other non-viral vectors market, 2014 - 2026 (USD Million)

Chapter 6 Gene Therapy Market: Regional Estimates & Trend Analysis, by Indications Type and Component Type
6.1 Gene Therapy market share by region, 2013 & 2024
6.2 North America
6.2.1 U.S.
6.2.2 Canada
6.3 Europe
6.3.1 Germany
6.3.2 U.K.
6.4 Asia Pacific
6.4.1 China
6.4.2 Japan
6.5 Latin America
6.5.1 Brazil
6.6 Middle East and Africa
6.6.1 South Africa

Chapter 7 Competitive Landscape
7.1 Strategy framework
7.2 Market participation categorization
7.3 Company Profiles
7.3.1 UniQure N.V
7.3.1.1 Company overview
7.3.1.2 Financial performance
7.3.1.3 Product benchmarking
7.3.1.4 Strategic initiatives
7.3.2 Spark Therapeutics LLC
7.3.2.1 Company overview
7.3.2.2 Financial performance
7.3.2.3 Product benchmarking
7.3.2.4 Strategic initiatives
7.3.3 Bluebird Bio
7.3.3.1 Company overview
7.3.3.2 Financial performance
7.3.3.3 Product benchmarking
7.3.3.4 Strategic initiatives
7.3.4 Celgene Corporation
7.3.4.1 Company overview
7.3.4.2 Financial Performance
7.3.4.3 Product benchmarking
7.3.4.4 Strategic initiatives
7.3.5 GlaxoSmithKline plc.
7.3.5.1 Company overview
7.3.5.2 Financial performance
7.3.5.3 Product benchmarking
7.3.5.4 Strategic initiatives
7.3.6 Shire Plc.
7.3.6.1 Company overview
7.3.6.2 Financial performance
7.3.6.3 Product benchmarking
7.3.6.4 Strategic initiatives
7.3.7 Cellectis
7.3.7.1 Company overview
7.3.7.2 Financial performance
7.3.7.3 Product benchmarking
7.3.7.4 Strategic initiatives
7.3.8 Sangamo Biosciences Inc.,
7.3.8.1 Company overview
7.3.8.2 Financial performance
7.3.8.3 Product benchmarking
7.3.8.4 Strategic initiatives
7.3.9 ReGenX Bio. Inc.,
7.3.9.1 Company overview
7.3.9.2 Financial performance
7.3.9.3 Product benchmarking
7.3.9.4 Strategic initiatives
7.3.10 Oxford Biomedica Plc.
7.3.10.1 Company overview
7.3.10.2 Financial performance
7.3.10.3 Product benchmarking
7.3.10.4 Strategic initiatives
7.3.11 Voyager Therapeutics
7.3.11.1 Company Overview
7.3.11.2 Financial performance
7.3.11.3 Product benchmarking
7.3.11.4 Strategic initiatives
7.3.12 Human Stem Cells Institute.
7.3.12.1 Company Overview
7.3.12.2 Financial performance
7.3.12.3 Product benchmarking
7.3.12.4 Strategic initiatives
7.3.13 Dimension Therapeutics Inc.
7.3.13.1 Company Overview
7.3.13.2 Financial performance
7.3.13.3 Product benchmarking
7.3.13.4 Strategic initiatives
7.3.14 Bristol Myers Squibb.
7.3.14.1 Company Overview
7.3.14.2 Financial performance
7.3.14.3 Product benchmarking
7.3.14.4 Strategic initiatives
7.3.15 Sanofi Genzyme.
7.3.15.1 Company Overview
7.3.15.2 Financial performance
7.3.15.3 Product benchmarking
7.3.15.4 Strategic initiatives
7.3.16 Applied Genetic Technologies Corporation.
7.3.16.1 Company Overview
7.3.16.2 Financial performance
7.3.16.3 Product benchmarking
7.3.16.4 Strategic initiatives
7.3.17 Chiesi Farmaceutici S.p.A
7.3.17.1 Company Overview
7.3.17.2 Financial performance
7.3.17.3 Product benchmarking
7.3.17.4 Strategic initiatives
7.3.18 Benitec BioPharma
7.3.18.1 Company Overview
7.3.18.2 Financial performance
7.3.18.3 Product benchmarking
7.3.18.4 Strategic initiatives
7.3.19 Sibiono GeneTech Co. Ltd
7.3.19.1 Company Overview
7.3.19.2 Financial performance
7.3.19.3 Product benchmarking
7.3.20 Shanghai Sunway Biotech Co. Ltd
7.3.20.1 Company Overview
7.3.20.2 Financial performance
7.3.21 Gensight Biologics S.A
7.3.21.1 Company Overview
7.3.21.2 Financial performance
7.3.21.3 Product benchmarking
7.3.21.4 Strategic initiatives
7.3.22 Transgene S.A
7.3.22.1 Company Overview
7.3.22.2 Financial performance
7.3.22.3 Product benchmarking
7.3.23 Epeius Biotechnologies Corp
7.3.23.1 Company Overview
7.3.23.2 Financial performance
7.3.23.3 Product benchmarking
7.3.24 Calimmune Inc.
7.3.24.1 Company Overview
7.3.24.2 Financial performance
7.3.24.3 Product benchmarking
7.3.25 American Gene Technologies
7.3.25.1 Company Overview
7.3.25.2 Financial performance
7.3.26 Juno Therapeutics, Inc.
7.3.26.1 Company overview
7.3.26.2 Financial performance
7.3.26.3 Product benchmarking
7.3.26.4 Strategic initiatives
7.3.27 Biomarin Pharmaceuticals, Inc.
7.3.27.1 Company overview
7.3.27.2 Financial performance
7.3.27.3 Product benchmarking
7.3.28 TaxusCardium Pharmaceuticals Inc.
7.3.28.1 Company overview
7.3.28.2 Financial performance
7.3.28.3 Product benchmarking
7.3.28.4 Strategic initiatives

List of Tables
Table 1 North America gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 2 North America gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 3 U.S. gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 4 U.S. gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 5 CANADA gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 6 CANADA gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 7 Europe gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 8 Europe gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 9 Germany gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 10 Germany gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 11 U.K. gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 12 U.K. gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 13 Asia Pacific gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 14 Asia Pacific gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 15 China gene therapy market, by system type, 2014 - 2026 (USD Million)
Table 16 China gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 17 Japan gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 18 Japan gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 19 Latin America gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 20 Latin America gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 21 Brazil gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 22 Brazil gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 23 Middle East and Africa gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 24 Middle East and Africa gene therapy market, by vector type, 2014 - 2026 (USD Million)
Table 25 South Africa gene therapy market, by indication type, 2014 - 2026 (USD Million)
Table 26 South Africa gene therapy market, by vector type, 2014 - 2026 (USD Million)

List of Figures
FIG. 1 Market summary
FIG. 2 Market trends & outlook
FIG. 3 Market segmentation & scope
FIG. 4 Market driver relevance analysis (Current & future impact)
FIG. 5 Market restrain relevance analysis (Current & future impact)
FIG. 6 Penetration & growth prospect mapping
FIG. 7 SWOT Analysis, By Factor (political & legal, economic and technological)
FIG. 8 Porter’s Five Forces Analysis
FIG. 9 Gene Therapy market Indication type outlook key takeaways
FIG. 10 Gene Therapy market: Indication Type movement analysis
FIG. 11 Global cancer market, 2014 - 2026 (USD Million)
FIG. 12 Global cardiovascular indication market, 2014 - 2026 (USD Million)
FIG. 13 Global Infectious diseases indication market, 2014 - 2026 (USD Million)
FIG. 14 Global Genetic diseases indication market, 2014 - 2026 (USD Million)
FIG. 15 Global Neurological diseases indication market, 2014 - 2026 (USD Million)
FIG. 16 Global other indications market, 2014 - 2026 (USD Million)
FIG. 17 Gene Therapy market vector type outlook: Key takeaways
FIG. 18 Gene Therapy market: vector type market: movement analysis
FIG. 19 Global viral vector market, 2014 - 2026 (USD Million)
FIG. 20 Global Retrovirus market, 2014 - 2026 (USD Million)
FIG. 21 Global Adenovirus market, 2014 - 2026 (USD Million)
FIG. 22 Global Adeno-associated market, 2014 - 2026 (USD Million)
FIG. 23 Global vaccinia virus market, 2014 - 2026 (USD Million)
FIG. 24 Global herpes simplex virus market, 2014 - 2026 (USD Million)
FIG. 25 Global other viral vector market, 2014 - 2026 (USD Million)
FIG. 26 Global non-viral vector market, 2014 - 2026 (USD Million)
FIG. 27 Global Injection of naked DNA market, 2014 - 2026 (USD Million)
FIG. 28 Global lipofection market, 2014 - 2026 (USD Million)
FIG. 29 Global other non-viral vectors market, 2014 - 2026 (USD Million)
FIG. 30 Regional market place: Key takeaways
FIG. 31 Regional outlook, 2015 & 2024
FIG. 32 Strategy framework
FIG. 33 Participant categorization

Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • UniQure N.V
  • Spark Therapeutics LLC
  • Bluebird Bio
  • Celgene Corporation
  • GlaxoSmithKline plc.
  • Shire Plc.
  • Cellectis
  • Sangamo Biosciences Inc.,
  • ReGenX Bio. Inc.,
  • Oxford Biomedica Plc.
  • Voyager Therapeutics
  • Human Stem Cells Institute.
  • Dimension Therapeutics Inc.
  • Bristol Myers Squibb.
  • Sanofi Genzyme.
  • Applied Genetic Technologies Corporation.
  • Chiesi Farmaceutici S.p.A
  • Benitec BioPharma
  • Sibiono GeneTech Co. Ltd
  • Shanghai Sunway Biotech Co. Ltd
  • Gensight Biologics S.A
  • Transgene S.A
  • Epeius Biotechnologies Corp
  • Calimmune Inc.
  • American Gene Technologies
  • Juno Therapeutics, Inc.
  • Biomarin Pharmaceuticals, Inc.
  • TaxusCardium Pharmaceuticals Inc.
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll